Skip to content Skip to footer
Subscribe Now
Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science
VIEWPOINTS

Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Shares Insights from Lilly’s Vision on New Stage of Metabolic Science

Shots: Leonard spoke about how Lilly is advancing in the field of metabolic disease research (esp. diabetes) He also talked about its lead candidate in type 2 diabetes and also discussed its clinical results in detail The interview summarizes Lilly’s objective to advance new discoveries and redefine diabetes care Smriti: Tell us how Lilly is leading…
August 16, 2022

Read more

PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022

Read more

PharmaShots Interview Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine

In an interview with PharmaShots, Eric Pearlman, Associate Vice President, Global & US Medical Affairs at Eli Lilly shared his views on the initiation of the patients enrollment in P-IV (CHALLENGE-MIG) head-to-head trial of Emgality for episodic migraine in adults Shots: The company initiate the patients' enrollment for the P-IV (CHALLENGE-MIG) head-to-head trial to evaluate the efficacy and safety of Emgality vs Nurtec ODT…
March 29, 2022

Read more

Load more